We are live on ! Find out more
GBT

Global Blood Therapeutics, Inc.
GBT

Delisted

GBT was delisted on the 4th of October, 2022.

Back to rankings

2 hedge funds and large institutions have $42.1K invested in Global Blood Therapeutics, Inc. in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 239 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 247 → 2 (-245)

100% less funds holding in top 10

Funds holding in top 10: 21 → 0 (-21)

100% less capital invested

Capital invested by funds: $4.73B → $42.1K (-$4.73B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 239

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-245
Holders Change %
-99.19%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-21
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
239
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$428M
2
BlackRock
BlackRock
New York
-$323M
3
BBA
Baker Bros. Advisors
New York
-$254M
4
PCM
Pentwater Capital Management
Florida
-$218M
5
State Street
State Street
Massachusetts
-$162M
Name Holding Trade Value Shares
Change 		Change in
Stake
DC
176
Diametric Capital
Massachusetts
– -$530K -7,778 Closed
GCP
177
GSA Capital Partners
United Kingdom
– -$529K -7,769 Closed
SC
178
Sagefield Capital
Texas
– -$497K -7,300 Closed
Victory Capital Management
179
Victory Capital Management
Texas
– -$490K -7,200 Closed
EFM
180
E Fund Management
China
– -$479K -7,030 Closed
SC
181
Shay Capital
New York
– -$463K -6,800 Closed
SMH
182
Sanders Morris Harris
Texas
– -$444K -6,500 Closed
CP
183
CenterBook Partners
Connecticut
– -$412K -6,046 Closed
CA
184
Calton & Associates
Florida
– -$409K -6,016 Closed
CF
185
Cantor Fitzgerald
New York
– -$409K -6,000 Closed
Parallax Volatility Advisers
186
Parallax Volatility Advisers
California
– -$356K -5,221 Closed
AIP
187
Ameritas Investment Partners
Nebraska
– -$344K -5,064 Closed
DIA
188
Dana Investment Advisors
Wisconsin
– -$345K -5,063 Closed
Prudential Financial
189
Prudential Financial
New Jersey
– -$324K -4,754 Closed
ONB
190
Old National Bancorp
Indiana
– -$305K -4,484 Closed
Mackenzie Financial
191
Mackenzie Financial
Ontario, Canada
– -$277K -4,061 Closed
MLICM
192
Metropolitan Life Insurance Company (MetLife)
New York
– -$267K -3,921 Closed
Amundi
193
Amundi
France
– -$260K -3,802 Closed
X
194
Xponance
Pennsylvania
– -$247K -3,624 Closed
Cambridge Investment Research Advisors
195
Cambridge Investment Research Advisors
Iowa
– -$246K -3,615 Closed
HHGC
196
Hunting Hill Global Capital
New York
– -$245K -3,596 Closed
TSS
197
Two Sigma Securities
New York
– -$242K -3,559 Closed
TAM
198
Tocqueville Asset Management
New York
– -$238K -3,500 Closed
PG
199
Pendal Group
Australia
– -$233K -3,420 Closed
LPL Financial
200
LPL Financial
California
– -$233K -3,419 Closed
6 7
8
9 10

GBT Hedge Fund Activity: Q4 2022 in Review

2 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q4 2022, worth a combined $42.1K — down 100% from $4.73B a quarter earlier.

Sellers outnumbered buyers: 239 funds closed out of GBT and 0 opened new positions — a net loss of 239 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $428M sold.

  • 2 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q4 2022, down from 247 in Q3 2022.
  • Funds reported $42.1K of Global Blood Therapeutics, Inc. stock for Q4 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Global Blood Therapeutics, Inc. positions in Q4 2022 and 239 closed out, a net change of -239 holders.
  • The largest Global Blood Therapeutics, Inc. seller in Q4 2022 was Vanguard Group, an estimated $428M sold.

Based on aggregated 13F filings for Q4 2022.